文献速递核素与放射性配体治疗肿瘤 PET/CT

DOTA-MGS5:一种优化靶向性能的胆囊收缩素-2受体靶向肽类似物及其诊疗应用

DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
PubMed 文献 · J Nucl Med · 2018-12-07

本研究开发了新型微小胃泌素类似物DOTA-MGS5,经111In、68Ga和177Lu标记后,在体外稳定性实验中显示出对酶降解的高度稳定性,在A431-CCK2R荷瘤小鼠中表现出高肿瘤摄取和良好靶本比,支持未来在进展期或转移性甲状腺髓样癌等CCK2R表达恶性肿瘤中开展临床诊疗研究。

要点

  • DOTA-MGS5经111In和177Lu标记后在不同介质中孵育至24小时稳定性显著提高。
  • 177Lu-DOTA-MGS5注射后1小时内小鼠血液中至少70%为完整放射性肽。
  • A431-CCK2R荷瘤小鼠中肿瘤摄取约20%ID/g(注射后1-4小时),A431-mock摄取可忽略。

核心结论

  • DOTA-MGS5具有优异的靶向性能,支持未来在进展期或转移性甲状腺髓样癌及其他晚期CCK2R表达恶性肿瘤患者中评估其诊断和治疗潜力。

研究设计与样本

  • 研究对DOTA-MGS5进行111In、68Ga和177Lu标记,开展广泛的体外稳定性研究。
  • 对177Lu-DOTA-MGS5在BALB/c小鼠中进行代谢研究。
  • 在转染人CCK2R的A431细胞(A431-CCK2R)及空载体对照(A431-mock)中研究受体亲和力和细胞摄取。
  • 使用A431-CCK2R/A431-mock异种移植的BALB/c裸鼠进行生物分布研究和小动物SPECT/CT。

主要发现

  • 111In和177Lu标记的DOTA-MGS5在不同介质中孵育至24小时对酶降解的稳定性高度增加。
  • 68Ga-DOTA-MGS5孵育至4小时观察到类似稳定性结果。
  • 注射177Lu-DOTA-MGS5后1小时内小鼠血液中至少70%检测为完整放射性肽。
  • 未标记肽及天然同位素复合物保留受体亲和力,放射性肽在A431-CCK2R细胞中4小时摄取超过60%。
  • 无论使用何种放射性金属标记,A431-CCK2R异种移植瘤摄取约20%注射活性/g(注射后1-4小时),A431-mock摄取可忽略,肿瘤/肾脏比值4-6。

临床怎么用

  • DOTA-MGS5的高靶向性能和良好显像对比度支持将其用于CCK2R表达肿瘤的诊疗一体化临床转化研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Molecular imaging and targeted radiotherapy with radiolabeled cholecystokinin-2 receptor (CCK2R) targeting peptide probes holds high promise to improve the clinical management of patients with metastatic medullary thyroid carcinoma and other CCK2R-expressing malignancies. Low stability and suboptimal targeting of currently available radiolabeled peptide analogs has prompted us to seek new stabilization strategies. In this study, we present a new minigastrin analog with site-specific C-terminal modifications showing a highly optimized targeting profile. Methods: DOTA-D-Glu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-NH2 (DOTA-MGS5) radiolabeled with 111In, 68Ga, and 177Lu was evaluated in extensive in vitro stability studies. For 177Lu-DOTA-MGS5, additional metabolic studies were performed on BALB/c mice. Receptor affinity and cell uptake were studied in A431 human epidermoid carcinoma cells transfected with human CCK2R (A431-CCK2R), as well as the same cell line transfected with the empty vector (A431-mock). A431-CCK2R/A431-mock xenografted athymic BALB/c nude mice were used for biodistribution studies and small-animal SPECT/CT. Results: DOTA-MGS5 radiolabeled with 111In and 177Lu showed a highly increased stability against enzymatic degradation in different media up to 24 h of incubation. Similar results were observed for 68Ga-DOTA-MGS5 incubated up to 4 h. In the blood of mice injected with 177Lu-DOTA-MGS5, at least 70% intact radiopeptide was detected up to 1 h after injection. The unlabeled peptide and the complexes with the natural isotopes showed retained receptor affinity, and the radiopeptides showed unexpectedly high cell uptake in A431-CCK2R cells (>60% at 4 h). Regardless of the radiometal used for labeling, impressively high uptake in A431-CCK2R xenografts was found (∼20% injected activity/g 1-4 h after injection), whereas the uptake in A431-mock xenografts was negligible. Low background activity and favorable tumor-to-kidney ratios (4-6) allowed for high image contrast in small-animal SPECT/CT. Conclusion: The excellent targeting properties of DOTA-MGS5 support future clinical studies evaluating the diagnostic and therapeutic potential in patients with progressive or metastatic medullary thyroid carcinoma, as well as other advanced-stage CCK2R-expressing malignancies.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Klingler M, Summer D, Rangger C, et al. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use. J Nucl Med. 2018. PMID: 30530828. doi:10.2967/jnumed.118.221283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。